Pharma BD Deal Intelligence
Collapsed before it paid off: Genentech's allogeneic T-cell collaboration with Adaptimmune, worth over $3B against a $150M upfront, was terminated by Genentech in April 2024 while the shared-target and personalized programs were still in discovery — Adaptimmune banked only the upfront plus about $35M in milestones.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →In 2021, the American Cancer Society projects 1,898,160 new cancer cases and 608,570 cancer deaths in the United States. Solid tumors represent approximately…
Roche's Genentech unit will pay Adaptimmune Therapeutics $150 million upfront and up to $3 billion more in milestones to develop allogeneic and personalized…
Adaptimmune receives FDA accelerated approval of TECELRA (afami-cel), first engineered cell therapy for a solid tumor (not part of Genentech deal).
Source summaries from our enrichment pipeline; follow links for originals.
All 16 sources with sentiment breakdown →
Genentech (a member of the Roche Group) and Adaptimmune entered a strategic collaboration on September 8, 2021 to research, develop and commercialize allogeneic (off-the-shelf) T-cell therapies against up to five shared cancer targets, plus personalized allogeneic T-cell programs. Adaptimmune received $150M upfront and was eligible for up to $150M in additional payments over five years, with total potential value exceeding $3B in development, regulatory and commercial milestones plus royalties. On April 12, 2024 Adaptimmune disclosed that Genentech had terminated the collaboration in its entirety (notice received on/around April 10, 2024; effective 180 days later, ~October 2024) while the allogeneic and personalized programs were still in discovery. Adaptimmune realized only the $150M upfront plus roughly $35M in milestone payments of the >$3B potential, and refocused on its late-stage autologous pipeline — afami-cel (TECELRA) won FDA accelerated approval on August 2, 2024 for synovial sarcoma, though that asset was not part of the Genentech collaboration.
1.9M US cases/yr · $164.0B Global oncology drug spending 2020 (USD MM) · 608570 US cancer deaths annually
Solid tumors collectively account for approximately 90% of US cancer incidence, with the American Cancer Society projecting 1.9 million new cancer diagnoses and 608,570 cancer deaths in 2021. The five highest-incidence solid tumor categories — breast, prostate, lung, colorectal, melanoma — together represent nearly half of new diagnoses. Despite the transformation produced by checkpoint inhibitors since 2011 (anti-PD-1, anti-PD-L1, anti-CTLA-4), durable responses remain limited to 15-25% of patients across most solid indications, driven by tumor heterogeneity, immune-excluded microenvironments, antigen escape, and HLA loss. Cell therapy in solid tumors has lagged hematologic CAR-T (Kymriah, Yescarta, Breyanzi, Carvykti, Abecma) due to barriers in trafficking, persistence, antigen specificity, and on-target/off-tumor toxicity. Engineered TCR T-cell therapies — which recognize intracellular peptide antigens presented on HLA — extend the addressable target universe beyond the surface proteome accessible to CARs, opening cancer-testis antigens (NY-ESO-1, MAGE-A4, PRAME), neoantigens, and viral antigens (HPV E6/E7) to T-cell therapy. Adaptimmune's lead afami-cel (afamitresgene autoleucel, MAGE-A4 SPEAR T) was in Phase 2 SPEARHEAD-1 in synovial sarcoma at deal date, on track for the first FDA-approved engineered TCR therapy.
The cell therapy competitive landscape in 2021 spans autologous CAR-T, allogeneic CAR-T, engineered TCR-T, TIL therapy, and CAR-NK. Approved autologous CAR-T: Kymriah (tisagenlecleucel, Novartis, CD19), Yescarta (axicabtagene ciloleucel, Gilead/Kite, CD19), Tecartus (brexucabtagene autoleucel, Kite, CD19), Breyanzi (lisocabtagene maraleucel, BMS, CD19), Abecma (idecabtagene vicleucel, BMS/Bluebird, BCMA). Engineered TCR competitors at deal date: Adaptimmune SPEAR T platform (afami-cel MAGE-A4, ADP-A2M4CD8 enhanced second-gen), Immatics (IMA203 PRAME, IMA401 bispecific TCR), Medigene (MDG1011), GSK letetresgene autoleucel (NY-ESO-1, partnered out 2021), TCR2 Therapeutics (TC-210/TC-510 mesothelin), T-knife. Allogeneic CAR-T: Allogene (ALLO-501/A CD19, ALLO-715 BCMA), Caribou (CB-010), Precision Bio (PBCAR0191), Atara (allogeneic EBV-T), CRISPR Therapeutics (CTX110/130). TIL therapy: Iovance lifileucel (LN-144, Phase 3 melanoma — approved Feb 2024 as Amtagvi). The Genentech/Adaptimmune deal targeted both allogeneic shared-target TCR-T and individualized neoantigen TCR-T, leveraging Genentech's neoantigen prediction stack (acquired via PERSONALIS partnership and BioNTech vaccine collaboration).
Adaptimmune disclosed (Apr 12, 2024) that Genentech terminated the 2021 collaboration in its entirety; notice ~Apr 10, 2024, effective 180 days later. Only $150M upfront + ~$35M milestones realized of >$3B potential; allogeneic/personalized programs still in discovery.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Adaptimmune Therapeutics plc (this deal) | 2021 | $3.3B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2021 deals · Roche Holding AG deals · Oncology deals